Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Levels of GHK-Cu decline significantly with age dropping from approximately 200 ng/mL in young adults to near undetectable levels by age 60
However, it is unsuitable for individuals with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
You are still within the standard or advanced dose range
Supported by trials like EMPA-REG, LEADER, and CANVAS, though large dedicated combination trials are still ongoing.
![In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
US$ 22.42
US$ 22.93
US$ 26.88
US$ 25.27
US$ 25.16
US$ 20.09
US$ 26.24
US$ 22.78
US$ 24.38
